Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 275

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1A
Chunk 275
---
 timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial
performance and stock price and could require us to delay or abandon our business plans. In addition, there is a risk that one or more
of our current clients, financial institutions or other third parties with whom we do business may be adversely affected by the foregoing
risks, which may have an adverse effect on our business.

The
dual-class structure of our common stock as contained in our Certificate of Incorporation has the effect of concentrating voting control
with those stockholders who held our Class B common stock. This ownership will limit or preclude your ability to influence corporate
matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all
or substantially all of our assets, or other major corporate transactions requiring stockholder approval, and that may adversely affect
the trading price of our Class A common stock.

Our
Class B common stock has 16.5 votes per share, and our Class A common stock has one vote per share. As of December 31, 2024, there were
833,334 shares of our Class B common stock outstanding, representing 79.6% of our total voting securities outstanding. Holders of all
of the issued and outstanding shares of our Class B common stock own 833,334 shares of Class B common stock representing approximately
60.5% of the voting power of our outstanding capital stock. Such Class B holders shall continue to have voting control until they hold
under 50.1% of the voting power of our outstanding capital stock, or approximately 583,000 shares of Class B common stock. In addition,
because of the 16.5-to-1 voting ratio between our Class B common stock and Class A common stock, the holders of our Class B common stock
could continue to control a majority of the combined voting power of our common stock and therefore control all matters submitted to
our stockholders for approval until converted by our Class B common stockholders. This concentrated control may limit or preclude your
ability to influence corporate matters for the foreseeable future, including the election of directors, amendments of our organizational
documents and any merger, consolidation, sale of all or substantially all of our assets or other major corporate transactions requiring
stockholder approval. In addition, this concentrated control may prevent or discourage unsolicited acquisition proposals or offers for
our capital stock that you may feel are in your best interest as one of our